← Leaderboards
Harry S Greenberg
University Of Michigan At Ann Arbor
$197,608
Attributed
$197,608
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$197,608 · 4
By mechanism
M01$197,608 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Maria G Castro$22,126,725
- Donna S. Shewach$6,336,350
- Pedro R Lowenstein$13,187,884
- Alnawaz Rehemtulla$11,324,080
- Joerg Lahann$3,367,884
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyHuman SubjectHuman Therapy EvaluationClinical ResearchGliomaClinical Trial Phase IDna RepairDrug Adverse EffectDrug Screening /EvaluationEnzyme TherapyGlioblastoma MultiformeIrinotecanMetalloenzymePharmacokineticsSarcomaTemozolomideThymidineAstrocytomaTissue Inhibitor Of MetalloproteinasesCarboplatinCarmustineClinical TrialsCombination ChemotherapyDna Damage
Grant awards (8)
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA$197,196
M01 · FY2002 · RR
Phase I/II trial of irinotecan in recurrent malignant glioma$0
M01 · FY2002 · RR
TEMOZOLOMIDE &BCNU FOR ANAPLASTIC GLIOMAS$0
M01 · FY2002 · RR
Thymidine &carboplatin chemotherapy for recurrent malignant glioma$0
M01 · FY2002 · RR
TEMOZOLOMIDE &BCNU FOR ANAPLASTIC GLIOMAS$206
M01 · FY2000 · RR
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA$206
M01 · FY2000 · RR
Thymidine &carboplatin chemotherapy for recurrent malignant glioma$0
M01 · FY2000 · RR
Phase I/II trial of irinotecan in recurrent malignant glioma$0
M01 · FY2000 · RR